SLN — Silence Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $137.44m
- -$9.89m
- $43.26m
- 22
- 32
- 15
- 11
Annual cashflow statement for Silence Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | 10-K | 10-K | 10-K |
| Standards: | IFRS | IFRS | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Net Income/Starting Line | -46.2 | -63.1 | -50.3 | -54.2 | -45.3 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 10.2 | 12.3 | 12.1 | 19.4 | 10.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 21.6 | 59.5 | -19.4 | -15.2 | -33 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -13.8 | 9.36 | -57 | -49.5 | -67.6 |
| Capital Expenditures | -0.659 | -1.83 | -0.545 | -0.056 | -0.211 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 13 | 13.8 | -20 | 19.4 | -21.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 12.3 | 11.9 | -20.5 | 19.3 | -22 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 19.8 | 42.2 | 52.6 | 31.9 | 142 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 17.9 | 63.4 | -33.1 | 2.52 | 52.5 |